Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Sep 11, 2026
Why Is Calumet (CLMT) Stock Up +1.35% Today?

Why Is Calumet (CLMT) Stock Up +1.35% Today?

Key Takeaways

  • CLMT shares rose +1.35% to close at $56.44, up from a prior close of $55.69.
  • The gain extended a powerful rally that has lifted the stock roughly 180% year to date, pushing it to fresh 52-week highs.
  • Primary driver: ongoing investor enthusiasm following the U.S. EPA's small refinery exemption decision, which reduced Calumet's renewable identification number (RIN) liability.
  • Secondary drivers include a flurry of analyst price-target increases and continued institutional accumulation of shares.
  • Traders are watching upcoming third-quarter results and any further resolution on Calumet's 2022–2024 partial exemptions.

Opening Summary

Calumet, Inc. (CLMT), a specialty products and renewable fuels manufacturer headquartered in Indianapolis, extended its multi-month advance on Wednesday, closing up +1.35% at $56.44 after finishing the prior session at $55.69. The Indianapolis-based company, which produces base oils, solvents, waxes, lubricants, and renewable fuels through its Montana Renewables business, traded as high as roughly $56.99 during the session, touching a fresh 52-week high. Markets attributed the move to sustained momentum from a favorable regulatory ruling and broader strength in the specialty chemicals and refining complex.

EPA Exemption Decision Eases a Key Overhang

The most significant catalyst behind CLMT's recent strength remains the U.S. Environmental Protection Agency's small refinery exemption decision, announced in early September. The EPA granted Calumet full exemptions on two refinery petitions for the 2025 compliance year, allowing the company to remove 71 million RINs from its balance sheet — a liability previously valued at approximately $170 million.

Under the Renewable Fuel Standard, refiners must either blend minimum volumes of renewable fuels or purchase RIN credits. Being freed from that obligation for the covered period directly reduces a compliance cost that has weighed on Calumet's cash flow and profitability. While a substantial RIN liability of roughly 129 million units — tied to partial exemptions from 2022 to 2024 — remains under EPA discussion and judicial review, the market has responded positively to the cleaner balance-sheet outlook, and the stock has continued to build on those gains.

Analyst Targets and Institutional Accumulation

Supporting the rally, several sell-side analysts raised their price targets following the regulatory news. H.C. Wainwright lifted its objective to $75 and reiterated a Buy rating, while Bank of America Securities raised its target to $60. The upgrades came against a backdrop of continued institutional buying: recent 13F filings showed established managers including BlackRock, UBS Asset Management, and BlueCrest Capital increasing their stakes, while the California State Teachers' Retirement System added a substantial position during the second quarter.

That accumulation has reinforced the narrative that CLMT is benefiting from greater index and institutional visibility, partly following the company's conversion from a master limited partnership to a standard C-corporation and its inclusion in several Russell indexes.

Specialty and Renewable Market Tailwinds

Beyond regulatory relief, Calumet's core businesses are enjoying favorable market dynamics. A structural supply imbalance in global paraffinic base oils — driven in part by geopolitical disruptions in the Middle East and Europe — has tightened supplies and supported pricing for Calumet's specialty output. At the same time, the company's Montana Renewables unit, a first-mover in sustainable aviation fuel, continues to scale up following the completion of its MaxSAF 150 expansion, backed by a U.S. Department of Energy loan guarantee.

Market Context and Trading Activity

The advance on Wednesday occurred on relatively lighter-than-average volume, suggesting the move was driven more by persistent upward momentum than by a single surge of new buying. Shares remain well above both their 50-day and 200-day moving averages, a sign of the strength of the underlying trend, though momentum indicators pointed to overbought conditions following the extended run. The stock's year-to-date gain of roughly 180% stands in sharp contrast to the broader market, highlighting how company-specific catalysts — rather than broad index performance — have powered the rally.

What Comes Next for CLMT

Looking ahead, investors will focus on Calumet's third-quarter earnings report, expected in early November, for evidence that higher specialty margins and reduced compliance costs are translating into improved profitability and cash flow. The company continues to work through a net-loss position and elevated leverage, which remain the central risks to the investment thesis. Additional attention will center on the outcome of discussions and legal review surrounding the 2022–2024 partial exemptions, as a favorable resolution could further reduce balance-sheet liabilities, while an adverse outcome could reverse some of the recent optimism.

Trending AI Robots

For traders seeking a more systematic approach to opportunities like this, Tickeron's Trending AI Robots page curates a selection of its strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in this curated section, giving users a focused view of strategies that are working right now. Explore the Trending AI Robots to see which automated strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CLMT

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


Momentum Indicator for CLMT turns positive, indicating new upward trend

CLMT saw its Momentum Indicator move above the 0 level on August 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for CLMT just turned positive on September 02, 2026. Looking at past instances where CLMT's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLMT advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 233 cases where CLMT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLMT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CLMT broke above its upper Bollinger Band on September 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (6.559). P/E Ratio (27.068) is within average values for comparable stocks, (36.582). CLMT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.076). CLMT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.020). P/S Ratio (1.071) is also within normal values, averaging (62.737).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 11.07B. The market cap for tickers in the group ranges from 47 to 212.8B. LIN holds the highest valuation in this group at 212.8B. The lowest valued company is GTBT at 47.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was -2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 6%. SSL experienced the highest price growth at 19%, while STDN experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 57
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 82
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
CLMT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a producer of specialty hydrocarbon products

Industry ChemicalsSpecialty

Profile
Details
Industry
Industrial Specialties
Address
1060 N Capitol Avenue
Phone
+1 317 328-5660
Employees
1540
Web
https://www.calumet.com
Interact to see
Advertisement
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.
CRCL surged +8.66% on Monday, March 9, 2026, rising from a prior close of $101.94 to trade at $110.77 intraday. The primary catalyst is a landmark stablecoin milestone: Circle's USDC overtook Tether as the dominant stablecoin by transfer volume, accounting for approximately 70% of all stablecoin transfer activity as total stablecoin transfers hit $1.8 trillion in February.
Carnival Corporation (CCL) shares fell approximately -7.60% in Monday's session, dropping from a Friday close of $25.79 to around $23.83. The primary catalyst is a broad market sell-off driven by intensifying recession fears, with the S&P 500 and consumer discretionary names bearing the brunt of the pressure.
Shares of Bloom Energy (BE) are surging approximately +10.30% in Monday's session, rebounding sharply from a steep -15.50% selloff on Friday, March 6, 2026. Friday's decline was triggered by an Oracle-OpenAI data center project update that spooked energy infrastructure investors; Monday's move reflects aggressive dip-buying and a sentiment reset.
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.
Shares of ARQ plunged approximately 27.50% in premarket trading on March 10, 2026, from a prior close of $3.20 to roughly $2.32. The primary catalyst was a deeply disappointing Q4 2025 earnings report, which revealed a net loss of $50.0 million for the quarter versus a net loss of $1.3 million in Q4 2024.
RAIL shares fell approximately 15% in premarket trading on March 10, 2026, following a steep after-hours reaction to disappointing Q4 2025 earnings results released after the close on March 9. The primary catalyst was a significant revenue miss: Q4 revenue came in at $125.6 million, well below consensus estimates near $144–$160 million, representing an 8.8% year-over-year decline.
ZVRA shares surged approximately +17.86% on March 10, 2026, driven by a blockbuster Q4 and full-year 2025 earnings report released before the market open. Primary catalyst: Q4 2025 EPS of $0.19 crushed the consensus estimate of $0.05 — a 280% beat — while revenue of $34.1 million exceeded forecasts by 21.57%.
LITE surged +14.73% on Monday, March 9, 2026, closing at $640.69 versus a prior close of $558.44 on March 6. The primary catalyst was the landmark $2 billion strategic investment by NVIDIA announced March 2, with the market continuing to price in its full implications following a brief post-announcement pullback.
Shares of BNTX fell approximately 22% on Tuesday, March 10, 2026, following a dual shock of disappointing full-year guidance and a surprise leadership upheaval. The primary catalyst was BioNTech's Q4 2025 earnings report, which included a 2026 revenue outlook of €2.0–€2.3 billion — well below analyst consensus and signaling continued pressure from declining COVID-19 vaccine demand.
CNC shares fell approximately 10% during Tuesday's session, extending a prolonged selloff in the managed care sector. The primary catalyst is intensifying investor concern over federal Medicaid and ACA funding cuts tied to the "One Big Beautiful Bill Act" (OBBBA), which threatens to shrink the government-sponsored insurance pools that Centene depends on for the majority of its revenue.
Technology recently peaked near 35% of the S&P 500 and has slipped over the last year, while Energy plus Materials remain near historically low combined weight at roughly 6%, which suggests the gap is still unusually wide.
Average daily equity purchases by retail investors on S&P 500 down days in 2026 are at the highest level on record, running about 100% above the peak intensity seen during the 2021 meme‑stock boom.
Over the past two weeks, PLTR has climbed from roughly the high‑130s to the mid‑150s, a gain of about 12–14%, with a series of strong up days between March 2 and March 6.
AVAV shares dropped approximately 10% in premarket trading on March 11, 2026, following a disappointing Q3 fiscal 2026 earnings report released after the prior session's close. Q3 revenue of $408.0 million came in far below analyst consensus of approximately $475–$488 million, representing a massive top-line miss.
KOS shares are down approximately 20% in premarket trading on March 11, 2026, having shed roughly 20.31% across the last two sessions (Tuesday close and premarket Wednesday). The primary catalyst is Kosmos Energy's announcement of a massive $185.25 million public equity offering priced at $1.90 per share — a steep discount to recent trading levels.